Verve Therapeutics announced that Troy Lister, Ph.D., currently serving as Verve’s senior vice president, research and early development, has been appointed chief scientific officer, effective June 21, 2024. Andrew Bellinger, M.D., Ph.D., who has served as CSO since 2019, will step down from this role and serve in an advisory capacity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERV:
- Verve Therapeutics to Participate in Upcoming Investor Conferences
- Verve Therapeutics COO buys $475.8K in common stock
- Verve Therapeutics’ Financial Outlook Threatened by CRISPR Patent Disputes
- Verve Therapeutics reports Q1 EPS (59c), consensus (71c)
- Verve Therapeutics announces dosing of first patient in VERVE-102 trial